<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-01T04:30:35Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/40476" metadataPrefix="marc">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/40476</identifier><datestamp>2026-02-03T11:35:33Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><record xmlns="http://www.loc.gov/MARC21/slim" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
   <leader>00925njm 22002777a 4500</leader>
   <datafield ind2=" " ind1=" " tag="042">
      <subfield code="a">dc</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Fuentes-Ríos, David</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Cepero, Ana</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">García-Castro, Miguel</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Contreras-Cáceres, Rafael</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">López-Romero, Juan Manuel</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Luque, Cristina</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Cabeza, Laura</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Melguizo, Consolación</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Prados, José</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="260">
      <subfield code="c">2022-02-05</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="520">
      <subfield code="a">Maslinic acid (MA), a pentacyclic triterpenoid obtained from olives that is characterized by its antiproliferative&#xd;
activity in tumor cells, has become a promising molecule that could be modi ed to improve cancer treatment. In&#xd;
this work we have synthesized in good yields several new MA conjugates, including glycerin, oligo(ethylene&#xd;
glycol), and amino acid derivatives (compounds 3a-f). The synthesis offers the possibility of recovering unreacted&#xd;
MA, and thus the scaling up of the process. For the tyramine-MA conjugate, compound 3f or TMA, the preparation&#xd;
has been optimized to a one-pot reaction. Solubility of conjugates in polar solvents has been measured, showing a&#xd;
marked increase of solubility with respect to MA. Moreover, we selected the tyramidyl maslinic acid conjugate (3f&#xd;
or TMA) to determine antitumor capacity over a wide range of cancer cell lines, including glioblastoma, mela-&#xd;
noma, breast, lung, colorectal and pancreatic cancer. Our results clearly demonstrated that TMA induced higher&#xd;
cytotoxicity in all cancer cell types compared to MA. TMA was more effective than MA, especially in breast cancer&#xd;
cells (MCF-7) and melanoma cells (B16–F10) where IC50 reductions of 4.12 and 4.72, respectively, was detected.&#xd;
Interestingly, TMA showed a remarkable antitumor ability against the resistant HCT-15 colon cancer cell line.&#xd;
Furthermore, we demonstrated for the rst time a relevant effect of a MA derivative against glioblastoma cells&#xd;
(A172 and SF-268). These results suggest that TMA is able to improve the antitumor characteristics of MA in a&#xd;
wide range of cancers and that it may be a promising compound for various tumor types, including resistant&#xd;
cancer.</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">European Journal of Medicinal Chemistry Reports 4 (2022) 100032</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://hdl.handle.net/10630/40476</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">10.1016/j.ejmcr.2022.100032</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Triterpenos</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Enlaces químicos</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Neurotransmisores</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Cáncer</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Citotoxicidad por mediación celular</subfield>
   </datafield>
   <datafield ind2="0" ind1="0" tag="245">
      <subfield code="a">Synthesis, solubility and antitumor activity of maslinic acid derivatives.</subfield>
   </datafield>
</record>
</metadata></record></GetRecord></OAI-PMH>